Company: SCLXW
Filing Date: 2025-12-29
Form Type: 424B3
Source: 0001193125-25-335429
Chunk: 348

Company: Scilex Holding Co
Filing Date: 2025-12-29
Form: 424B3
Chunk 348
---
 Chapter 11 of the United States Bankruptcy Code in the Bankruptcy Court, jointly administered under the caption In re Sorrento Therapeutics, Inc., et al.(Case Number: 23-90085 (DRJ)).While we were majority-owned by Sorrento when the voluntary proceedings were commenced, we were not (and are not) a debtor in Sorrento’s voluntary Chapter 11 filing. As of September 21, 2023, Sorrento no longer held a majority of the voting power of our outstanding capital stock entitled to vote. At the time of the Chapter 11 filing, Dr. Ji was and continues to serve as Chairman of the board of directors, President and Chief Executive Officer of Sorrento; Mr. Shah was serving as a director of Sorrento and served as a director until November 2023 and served as our Chief Executive Officer and President until August 17, 2025 and served as one of our directors until September 22, 2025; Dr. Wu was serving as a director of Sorrento and served as a director until April 2024; and Mr. Followwill was serving as a director of Sorrento and served as a director until April 2024. Board Composition Our business and affairs are managed under the direction of our Board, which currently consists of six members. Dr. Ji serves as Chairperson of our Board. The primary responsibilities of our Board are to provide oversight, strategic guidance, counseling and direction to our management. Our Board meets on a regular basis and on an ad hocbasis as required. In accordance with the terms of our Certificate of Incorporation and our Bylaws, our Board is divided into three classes with staggered three-year terms, as follows:

| • |     | The Class I director is Dorman Followwill, and his term will expire at our annual meeting of stockholders to 
 be held in 2026;                                                                                             |

| • |     | The Class II directors are Jay Chun, M.D., Ph.D. and Yue Alexander Wu, Ph.D. and their term will expire at 
 our annual meeting of stockholders to be held in 2027; and                                                 |

| • |     | The Class III directors are Henry Ji, Ph.D. and Stephen Ma, and their term will expire at our annual meeting 
 of stockholders to be held in 2028.                                                                          |

231

At each annual meeting of stockholders, the successors to directors whose terms will then
expire will be elected